Tuesday, June 12, 2012
BioSante Pharmaceuticals Inc., of Lincolnshire, Ill., said that it will embark on two new Phase III efficacy trials of LibiGel, a testosterone therapy for female sexual dysfunction, and that it will continue ongoing LibiGel Phase III cardiovascular and breast cancer safety studies.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.